Sponsored by the Academy for Continued Healthcare Learning
This activity is supported by an educational grant from Gilead Sciences, Inc.
Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are chronic, systemic, autoimmune disorders characterized by inflammatory processes. There are numerous classes of therapies available to treat RA and IBD, and some patients achieve low disease activity or remission, yet a proportion of patients exhibits an inadequate response and/or discontinues therapy due to tolerability. As such, investigations into new targets and therapies, such as the janus kinase (JAK) inhibitors, continue. The introduction of JAK inhibitors further contributes to a growing armamentarium of therapies for these immune-mediated inflammatory diseases. Evolving strategies for employing the JAK inhibitors present a decision-making challenge to clinicians who treat these patients.
Bring this content to your institution! To educate your staff and earn additional CME credit, please contact Michelle Forcier at 773-714-0705 x118.
This activity is intended for gastroenterologists, rheumatologists and other clinicians interested in learning more about the JAK/STAT signaling pathway.
Upon completion of this activity, participants will be able to:
Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of immune-mediated inflammatory diseases
Evaluate the use of JAK inhibitors in immune-mediated inflammatory diseases such as RA and IBD
Interpret clinical trial efficacy and safety data of JAK inhibitors under investigation across inflammatory diseases
Outline approaches to educating patients on the role of JAK inhibition, including efficacy and safety data
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Russell Cohen, MD (Moderator) Professor of Medicine Directory, Inflammatory Bowel Disease Center Co-Director, Advanced IBD Fellowship Program University of Chicago Medical Center Chicago, IL
William Rigby, MD (Faculty) Professor of Medicine, Microbiology and Immunology Division of Rheumatology Vice Chairman, Academic Affairs Department of Medicine Dartmouth Medical School Dartmouth-Hitchcock Medical Center Lebanon, NH
Dr. Rigby discloses the following: Consulting Agreements: Bristol-Myers Squibb, Pfizer Inc., Roche
Joel Pekow, MD (Faculty) Assistant Professor of Medicine Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine and Biological Sciences Chicago, IL
Dr. Pekow discloses the following: Sources of Funding for Research: AbbVie, Takeda Pharmaceuticals, Inc. Consultant/Advisory Board: Janssen, Pfizer, Inc., Verastem Inc.
Accredited Provider Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: JAK inhibitors under investigation for RA and IBD.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
To obtain credit, a score of 75% on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
Inquiries may be directed to ACHL at (877) 444-8435 x228.